DOI QR코드

DOI QR Code

Development of Polymeric Nanopaclitaxel and Comparison with Free Paclitaxel for Effects on Cell Proliferation of MCF-7 and B16F0 Carcinoma Cells

  • Yadav, Deepak ;
  • Anwar, Mohammad Faiyaz ;
  • Garg, Veena ;
  • Kardam, Hemant ;
  • Beg, Mohd Nadeem ;
  • Suri, Suruchi ;
  • Gaur, Sikha ;
  • Asif, Mohd
  • Published : 2014.03.01

Abstract

Paclitaxel is hydrophobic in nature and is recognized as a highly toxic anticancer drug, showing adverse effects in normal body sites. In this study, we developed a polymeric nano drug carrier for safe delivery of the paclitaxel to the cancer that releases the drug in a sustained manner and reduces side effects. N-isopropylacrylamide/vinyl pyrrolidone (NIPAAm/VP) nanoparticles were synthesized by radical polymerization. Physicochemical characterization of the polymeric nanoparticles was conducted using dynamic light scattering, transmission electron microscopy, scanning electron microscopy and nuclear magnetic resonance, which confirmedpolymerization of formulated nanoparticles. Drug release was assessed using a spectrophotometer and cell viability assays were carried out on the MCF-7 breast cancer and B16F0 skin cancer cell lines. NIPAAm/VP nanoparticles demonstrated a size distribution in the 65-108 nm range and surface charge measured -15.4 mV. SEM showed the nanoparticles to be spherical in shape with a slow drug release of ~70% in PBS at $38^{\circ}C$ over 96 h. Drug loaded nanoparticles were associated with increased viability of MCF-7 and B16F0 cells in comparison to free paclitaxel. Nano loaded paclitaxel shows high therapeutic efficiency by sustained release action for the longer period of time, i increasing its efficacy and biocompatibility for human cancer therapy. Therefore, paclitaxel loaded (NIPAAm/VP) nanoparticles may provide opportunities to expand delivery of the drug for clinical selection.

Keywords

NIPAAm/VP nanoparticles;paclitaxel;sustain drug delivery;cancer cell lines MCF-7;B16F0

References

  1. Trubetskoy VS (1999). Polymeric micelles as carriers of diagnostic agents. Adv Drug Deliv Rev, 37, 81-8. https://doi.org/10.1016/S0169-409X(98)00100-8
  2. Surapaneni MS, Das SK, Das NG (2012). Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmaco, 2012, 623139.
  3. Tabar L, Dean PB (2004). Mammography and breast cancer: the new era. Int J Gynaecol Obstet, 82, 319-26.
  4. Verderio P, Bonetti P, Colombo M, Pandolfi L, Prosperi D (2013). Intracellular drug release from curcumin-loaded PLGA nanoparticles induces G2/M block in breast cancer cells. Biomacromole, 14, 672-82. https://doi.org/10.1021/bm3017324
  5. Verma AK, Chanchal A, Maitra A (2010). Co-polymeric hydrophilic nanospheres for drug delivery: Release kinetics and cellular uptakes. Ind J Exp Bio, 48, 1043-52.
  6. Wang M, Thanou M (2010). Targeting nanoparticles to cancer. Pharmacol Res, 62, 90-9. https://doi.org/10.1016/j.phrs.2010.03.005
  7. Wang YM, Sato H, Adachi I, Hirikoshi I (1996). Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent. Taxol Chem Pharm Bull, 44, 1935-40. https://doi.org/10.1248/cpb.44.1935
  8. Ward MA, Georgiou TK (2011). Thermoresponsive polymers for biomedical applications. Polymers, 3, 1215-42. https://doi.org/10.3390/polym3031215
  9. Yang D, Van S, Jiang X, Yu L (2011). Novel free paclitaxel-loaded poly(L-y-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomed, 6, 85-91.
  10. Rfsler A, Vandermeulen GM, Klok HA (2001). Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev, 53, 95-108. https://doi.org/10.1016/S0169-409X(01)00222-8
  11. Mashinchian O, Salehi R, Dehghan G, et al (2010). Novel thermosensitivepoly (N-isopropylacrylamide-covinylpyrrolidone-co-methacrylic acid) nanosystems for delivery of natural products. Inter J Drug Del, 2, 278-86. https://doi.org/10.5138/ijdd.2010.0975.0215.02039
  12. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63. https://doi.org/10.1016/0022-1759(83)90303-4
  13. Petros RA, DeSimone JM (2010). Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov, 9, 615-27. https://doi.org/10.1038/nrd2591
  14. Rosler A, Vandermeulen GW, Klok HA (2001). Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Del Rev, 53, 95-108. https://doi.org/10.1016/S0169-409X(01)00222-8
  15. Sharma A, Straubinger RM (1994). Novel taxol formulations: preparation and characterization of Taxol containing liposomes. Pharm Res, 11, 889-96. https://doi.org/10.1023/A:1018994111594
  16. Shroff K, Kokkoli E (2012). PEGylated liposomal doxorubicin targeted to $I{\pm}I^21$-expressing MDA-MB-231 breast cancer cells. Langmuir, 28, 4729-36. https://doi.org/10.1021/la204466g
  17. Lerner BH (2001). Breast Cancer Wars. Oxford University Press. New York.
  18. Kikuchi A, Okano T (1998). Biorelated Polymers and Gels. Academic Press, Boston, MA, 1-28.
  19. Kwon GS, Okano T (1996). Polymeric micelles as new drug carriers. Adv Drug Deliv Rev, 21, 107-16. https://doi.org/10.1016/S0169-409X(96)00401-2
  20. Lee J, Lee SC, Acharya G, Chang C, Park K (2003). Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res, 20, 1022-30. https://doi.org/10.1023/A:1024458206032
  21. Liechty WB, Peppas NA (2012). Expert opinion: Responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm, 80, 241-6. https://doi.org/10.1016/j.ejpb.2011.08.004
  22. Ludenberg BB (1997). A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol, 49, 16-21. https://doi.org/10.1111/j.2042-7158.1997.tb06744.x
  23. Marshall CJ (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signalregulated kinase activation. Cell, 80, 179-85. https://doi.org/10.1016/0092-8674(95)90401-8
  24. Gurses N, Topcul M (2013) The effect of abraxane on cell kinetic parameters of HeLa cells. Asian Pac J Cancer Prev, 14, 4229-33. https://doi.org/10.7314/APJCP.2013.14.7.4229
  25. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A, 108, 1850-5. https://doi.org/10.1073/pnas.1011379108
  26. Fonseca C, Simoes S, Gaspar R (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Rel, 83, 273-86. https://doi.org/10.1016/S0168-3659(02)00212-2
  27. Goldspiel BR (1997). Clinical overview of the taxanes. Pharmacothe, 17, 110-25.
  28. Hamidi M, Azadi A, Rafiei P (2008). Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev, 60, 1638-49. https://doi.org/10.1016/j.addr.2008.08.002
  29. Jabbari E, Yang X, Moeinzadeh S, He X (2013). Drug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles. Eur J Pharm Biopharm, 84, 49-62. https://doi.org/10.1016/j.ejpb.2012.12.012
  30. Jeong B, Bae YH, Kim SW (1999). Thermoreversible gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions. Macromol, 32, 7064-9. https://doi.org/10.1021/ma9908999
  31. Kataoka K, Harada A, Nagasaki Y (2001). Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev, 47, 113-31. https://doi.org/10.1016/S0169-409X(00)00124-1
  32. Deng C, Jiang Y, Cheng R, Meng F, Zhong Z (2012). Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects. Nano Today, 7, 467-480. https://doi.org/10.1016/j.nantod.2012.08.005
  33. Bartoli MH, Boitard M, Fessi H, et al (1990). In vitro and in vivo antitumoral activity of free and encapsulated Taxol. J Microencapsul, 7, 191-7. https://doi.org/10.3109/02652049009021832
  34. Chen DB, Yang TZ, Lu WL, Zhang Q (2001). In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing Paclitaxel. Chem Pharm Bull, 49, 1444-7. https://doi.org/10.1248/cpb.49.1444
  35. Crosasso P, Ceruti M, Brusa P, et al (2000). Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Rel, 63, 19-30. https://doi.org/10.1016/S0168-3659(99)00166-2

Cited by

  1. Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7113
  2. Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10281
  3. Nanoparticles Promise New Methods to Boost Oncology Outcomes in Breast Cancer vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1683
  4. Effect of Paclitaxel-loaded Nanoparticles on the Viability of Human Hepatocellular Carcinoma HepG2 Cells vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1725